Multivariable analyses of cGVHD occurrence by biomarker thresholds
| Marker∗ . | HR (95% CI) . | P value . |
|---|---|---|
| CXCL9 | ||
| Overall | 2.70 (1.29-5.65) | .01 |
| ≤10 y | 19.0 (3.38-107) | <.001 |
| >10 y | 2.31 (1.00-5.34) | .05 |
| IL1RL1 | ||
| Overall | 2.20 (1.3- 3.53) | .001 |
| ≤10 y | 2.10 (0.87-5.05) | .10 |
| >10 y | 2.12 (1.19-3.78) | .01 |
| REG3α | ||
| Overall | 1.75 (1.11-2.75) | .02 |
| ≤10 y | 1.70 (0.71-4.10) | .24 |
| >10 y | 1.78 (1.03-3.08) | .04 |
| MMP3 | ||
| Overall | 1.85 (1.14-3.01) | .01 |
| ≤10 y | 1.60 (0.64-3.96) | .31 |
| >10 y | 2.40 (1.27-4.54) | .01 |
| DKK3 | ||
| Overall | 1.94 (1.16-3.22) | .01 |
| ≤10 y | 1.37 (0.55-3.40) | .49 |
| >10 y | 1.97 (1.03-3.75) | .04 |
| sCD163 | ||
| Overall | 1.23 (0.74-2.05) | .42 |
| ≤10 y | 0.62 (0.22-1.77) | .37 |
| >10 y | 1.89 (1.01-3.55) | .05 |
| Marker∗ . | HR (95% CI) . | P value . |
|---|---|---|
| CXCL9 | ||
| Overall | 2.70 (1.29-5.65) | .01 |
| ≤10 y | 19.0 (3.38-107) | <.001 |
| >10 y | 2.31 (1.00-5.34) | .05 |
| IL1RL1 | ||
| Overall | 2.20 (1.3- 3.53) | .001 |
| ≤10 y | 2.10 (0.87-5.05) | .10 |
| >10 y | 2.12 (1.19-3.78) | .01 |
| REG3α | ||
| Overall | 1.75 (1.11-2.75) | .02 |
| ≤10 y | 1.70 (0.71-4.10) | .24 |
| >10 y | 1.78 (1.03-3.08) | .04 |
| MMP3 | ||
| Overall | 1.85 (1.14-3.01) | .01 |
| ≤10 y | 1.60 (0.64-3.96) | .31 |
| >10 y | 2.40 (1.27-4.54) | .01 |
| DKK3 | ||
| Overall | 1.94 (1.16-3.22) | .01 |
| ≤10 y | 1.37 (0.55-3.40) | .49 |
| >10 y | 1.97 (1.03-3.75) | .04 |
| sCD163 | ||
| Overall | 1.23 (0.74-2.05) | .42 |
| ≤10 y | 0.62 (0.22-1.77) | .37 |
| >10 y | 1.89 (1.01-3.55) | .05 |
Controlling for White/non-Hispanic (yes/no), malignant vs nonmalignant, graft source, GVHD prophylaxis, and ATG/alemtuzumab use. Sample sizes for models were overall, N = 278; ≤10 years, n = 121; >10 years, n = 157, except for models for DKK3 and sCD163 in which sample sizes were overall, N = 231; ≤10 years, n = 102; >10 years, n = 129.
Markers dichotomized at selected thresholds.